PMID- 30535502
OWN - NLM
STAT- MEDLINE
DCOM- 20190401
LR  - 20211206
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 54
IP  - 2
DP  - 2019 Feb
TI  - MicroRNA‑143‑3p suppresses cell growth and invasion in laryngeal squamous cell 
      carcinoma via targeting the k‑Ras/Raf/MEK/ERK signaling pathway.
PG  - 689-701
LID - 10.3892/ijo.2018.4655 [doi]
AB  - MicroRNAs (miRNAs or miRs) have been identified as an important regulator in 
      carcinogenesis and other pathological processes. However, the molecular mechanism 
      underlying the function of miRNAs in the progression and development of laryngeal 
      squamous cell carcinoma (LSCC) remains to be fully elucidated. In the present 
      study, the miRNA expression pattern in LSCC tissues was profiled using miRNA 
      microarray analysis. It was found that a large set of miRNAs are aberrantly 
      expressed in LSCC tissues and that miR‑143‑3p was the most markedly downregulated 
      compared with normal tissues. The low expression of miR‑143‑3p was associated 
      with poor prognosis in LSCC. The overexpression of miR‑143‑3p repressed cellular 
      proliferation and induced apoptosis in vitro, and inhibited tumor growth in vivo. 
      The upregulation of miR‑143‑3p suppressed cell migration and invasion through 
      inhibiting the epithelial‑mesenchymal transition cascade. In addition, it was 
      verified that the oncogene k‑Ras is a target of miR‑143‑3p in LSCC cells, and the 
      suppressive effects of miR‑143‑3p on LSCC cells were abrogated by the 
      overexpression of k‑Ras. It was also revealed that miR‑143‑3p may inhibit cell 
      growth and metastasis through targeting the k‑Ras/Raf/mitogen‑activated protein 
      kinase kinase (MEK)/extracellular signal‑regulated kinase (ERK) signaling 
      pathway. Taken together, the data indicated that the miR‑143‑3p/k‑Ras/Raf/MEK/ERK 
      axis serves a key regulator in the development and progression of LSCC, 
      suggesting that miR‑143‑3p may be a potential prognostic biomarker and 
      therapeutic target in the treatment of LSCC.
FAU - Zhang, Feng
AU  - Zhang F
AD  - Ear Nose and Throat Hospital, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan 450052, P.R. China.
FAU - Cao, Hua
AU  - Cao H
AD  - Ear Nose and Throat Hospital, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan 450052, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181206
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (KRAS protein, human)
RN  - 0 (MIRN143 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.11.1 (raf Kinases)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinogenesis/genetics
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Disease-Free Survival
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - MAP Kinase Signaling System
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Invasiveness/genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - raf Kinases/*genetics
OTO - NOTNLM
OT  - microRNAs
OT  - laryngeal squamous cell carcinoma
OT  - microRNA 143 3p
OT  - cell growth
OT  - metastasis
OT  - k Ras/Raf/MEK/ERK pathway
EDAT- 2018/12/12 06:00
MHDA- 2019/04/02 06:00
CRDT- 2018/12/12 06:00
PHST- 2017/11/23 00:00 [received]
PHST- 2018/07/02 00:00 [accepted]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/04/02 06:00 [medline]
PHST- 2018/12/12 06:00 [entrez]
AID - 10.3892/ijo.2018.4655 [doi]
PST - ppublish
SO  - Int J Oncol. 2019 Feb;54(2):689-701. doi: 10.3892/ijo.2018.4655. Epub 2018 Dec 6.